Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC
Brief Summary: This is a two-arm, parallel, open-label, Phase 2 multicenter study of pemetrexed as first line combination therapy with either cisplatin or carboplatin in the palliative setting of stage IIIb and IV non-small cell lung cancer patients. Approximately 130 patients will be included in about 15 centers in Germany and randomized to one of the above treatment regimens in a 1:1 ratio. Chemotherapy will be administered over a maximum of six cycles with a standard length of 21 days. Primary objective will be the Progression Free Survival Time of patients as assessed in both treatment arms.


Options:
A: Arm Label: Arm I (paclitaxel and carboplatin); Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: carboplatin, Other: laboratory biomarker analysis | Arm Label: Arm II (paclitaxel, carboplatin, and bevacizumab); Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: carboplatin, Biological: bevacizumab, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab)
B: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Pemetrexed + Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Pemetrexed + Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Carboplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed + Carboplatin, Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pemetrexed + Carboplatin
D: Arm Label: Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab 200 mg, Drug: Cisplatin, Drug: Carboplatin, Drug: Pemetrexed, Dietary Supplement: Folic acid 350-1000 μg, Dietary Supplement: Vitamin B12 1000 μg, Drug: Dexamethasone 4 mg | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Carboplatin, Drug: Pemetrexed, Dietary Supplement: Folic acid 350-1000 μg, Dietary Supplement: Vitamin B12 1000 μg, Drug: Dexamethasone 4 mg, Drug: Saline solution | Intervention Type: BIOLOGICAL; Name: Pembrolizumab 200 mg; Assigned to Arm(s): Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid 350-1000 μg; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12 1000 μg; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Dexamethasone 4 mg; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): Control

Answer: C